A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Exclusion Criteria

• •Aphakic or pseudophakic with intraocular lens outside of the capsular bag
• •Previous laser photocoagulation or IVT anti-vascular endothelial growth factor (VEGF) for CNV, diabetic macular edema (DME), retinal vein occlusion (RVO), or proliferative diabetic retinopathy
• •Active or history of CNV
• •\- Non-functioning non-study eye, defined as either: BCVA of hand motion or worse and/or no physical presence of eye
• •Macular atrophy in either eye due to causes other than AMD
• •Part 2: Evidence of prior or active CNV
• •Prior treatment with any approved therapy for GA (Syfovre, Izervay) in either eye for Part 1A and Part 2 ≤ 20 weeks prior to Day 1. For Part 1B, prior treatment with any approved therapy for GA (Syfovre, Izervay) in the study eye ≤ 20 weeks prior to Day 1